Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (Q34263959)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial |
scientific article |
Statements
1 reference
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (English)
1 reference
Vincent A Miller
1 reference
Vera Hirsh
1 reference
Jacques Cadranel
1 reference
Yuh-Min Chen
1 reference
Keunchil Park
1 reference
Sang-We Kim
1 reference
Caicun Zhou
1 reference
Wu-Chou Su
1 reference
Mengzhao Wang
1 reference
Yan Sun
1 reference
Dae Seog Heo
1 reference
Lucio Crino
1 reference
Eng-Huat Tan
1 reference
Tsu-Yi Chao
1 reference
Mehdi Shahidi
1 reference
Xiuyu Julie Cong
1 reference
Robert M Lorence
1 reference
James Chih-Hsin Yang
1 reference
26 March 2012
1 reference
1 reference
Identifiers
1 reference